Jump to content

Recombinant human epidermal growth factor: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Specified application of Heberprot-P to terminal foot ulcers of Wagner grade 3, 4 & 5
Added reference to Wagner Scale
Line 5: Line 5:


'''Heberprot-P''' is a drug developed in Cuba as a cure for [[diabetic foot ulcer]].{{citation needed|date=December 2013}} The product contains [[epidermal growth factor]] (EGF) to be applied by intra-lesional injections directly in the wound site.<ref>{{cite web|url=http://heberprot-p.cigb.edu.cu/index.php?option=com_content&view=article&id=17&Itemid=32&lang=en |title=Prescription Information |publisher=Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba |year=2010|accessdate=2012-09-08}}</ref>{{primary source-inline|date=December 2013}} It has been found to "promote granulation and healing in advanced diabetic foot ulcers".<ref>{{cite web|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1742-481X.2009.00641.x/full |title=Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study |publisher=International Wound Journal |date=December 2009|pages= 432–443| doi= 10.1111/j.1742-481X.2009.00641.x |accessdate=2012-09-08}}</ref>
'''Heberprot-P''' is a drug developed in Cuba as a cure for [[diabetic foot ulcer]].{{citation needed|date=December 2013}} The product contains [[epidermal growth factor]] (EGF) to be applied by intra-lesional injections directly in the wound site.<ref>{{cite web|url=http://heberprot-p.cigb.edu.cu/index.php?option=com_content&view=article&id=17&Itemid=32&lang=en |title=Prescription Information |publisher=Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba |year=2010|accessdate=2012-09-08}}</ref>{{primary source-inline|date=December 2013}} It has been found to "promote granulation and healing in advanced diabetic foot ulcers".<ref>{{cite web|url=http://onlinelibrary.wiley.com/doi/10.1111/j.1742-481X.2009.00641.x/full |title=Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study |publisher=International Wound Journal |date=December 2009|pages= 432–443| doi= 10.1111/j.1742-481X.2009.00641.x |accessdate=2012-09-08}}</ref>
Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 & 5 of Wagner’s Classification with average ulcer size bigger than 20 cm2, of both neuropathic and ischemic etiology with high risk amputation.
Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 & 5 of Wagner’s Classification<ref>http://clinical.diabetesjournals.org/content/27/2/52/T1.expansion.html</ref> with average ulcer size bigger than 20 cm2, of both neuropathic and ischemic etiology with high risk amputation.


==Clinical trials and use==
==Clinical trials and use==

Revision as of 14:27, 19 October 2014

Heberprot-P is a drug developed in Cuba as a cure for diabetic foot ulcer.[citation needed] The product contains epidermal growth factor (EGF) to be applied by intra-lesional injections directly in the wound site.[1][non-primary source needed] It has been found to "promote granulation and healing in advanced diabetic foot ulcers".[2] Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 & 5 of Wagner’s Classification[3] with average ulcer size bigger than 20 cm2, of both neuropathic and ischemic etiology with high risk amputation.

Clinical trials and use

The drug is currently in use in Cuba, Argentina, Colombia, Costa Rica, Ecuador, Guatemala, Mexico, Panamá [4], Paraguay, Peru, Uruguay, Venezuela, Russia and in the Domenican Republicand, Vietnam, and the Philippines. It has been submitted for patent examination in Canada.[5] As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union.[citation needed] These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.[6]

The drug has been available in Algeria since 2008, and has seen use in 31 hospitals in the country.[citation needed] It was used on 314 patients, with a success rate of 90%.[citation needed] A local firm has applied to manufacture the drug in Algeria.[7][better source needed]

In South east Asian countries such as Vietnam and the Philippines, this innovative biotech drug for preventing lower extremities amputation due to severe diabetic foot ulcers is being used as an advanced wound care healing drug and may be accessed through wound care clinics or wound care specialists among hospitals.[neutrality is disputed][citation needed]

The drug and clinical trials have been looked over by scientists in the USA, calling the drug "very clever"[This quote needs a citation], but the political situation between Cuba and the USA may have some effect on the drug being formally evaluated in the USA.[8][neutrality is disputed]

References

  1. ^ "Prescription Information". Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba. 2010. Retrieved 2012-09-08.
  2. ^ "Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study". International Wound Journal. December 2009. pp. 432–443. doi:10.1111/j.1742-481X.2009.00641.x. Retrieved 2012-09-08.
  3. ^ http://clinical.diabetesjournals.org/content/27/2/52/T1.expansion.html
  4. ^ Panamá Technical File in the Public Health Database
  5. ^ "Canadian Patents Database, Patent Summary: USE OF A TOPICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUTATION PREVENTION". Canadian Intellectual Property Office. 2006-12-28. Retrieved 2012-09-08.
  6. ^ "China, Russia to test Cuban diabetes drug". Xinhua English. 2012-07-20. Retrieved 2012-09-09.
  7. ^ "L'Heberprot-P sauve 196 malades en Algérie: Traitement contre l'ulcère du pied diabétique". DjaZairess.com in French. 2009-12-09. Retrieved 2014-06-18.
  8. ^ "Cubans developing therapy for diabetic ulcers Treatment said to save limbs; U.S. scientist hails research, urges more tests". MSNBC. 2006-11-01. Retrieved 2012-09-08.

http://news.cubasi.cu/index.php?option=com_k2&view=item&id=1436:vietnam-gains-interest-in-cuban-medicine-heberprot-p

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Recombinant_human_epidermal_growth_factor&oldid=630241039"